References
- Singh J, Edwards NL. Gout management and outcomes during the COVID-19 pandemic in late 2020–2021: A cross-sectional internet survey [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Helget L, England B, Roul P, et al. Mortality in patients with sub-optimally treated gout in the Veteran’s Health Administration: A national retrospective cohort study [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- O’Dell J, Neogi T, Pillinger M, et al. Urate lowering therapy in the treatment of gout: A multicenter, randomized, double-blind comparison of allopurinol and febuxostat using a treat-to-target strategy [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Edwards NL, LaMoreaux B, Vitriol J, Magerman A. Gout stigma: Investigating the existence of gout stigma and its impact on patient perceptions and treatment decisions [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Tiku A, Boudville N, Brown F, et al. Urate-lowering therapy for prevention of gout: Prespecified analyses from the CKD-FIX trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Singh J, Saag K, Baker J, et al. A behavioral intervention to improve gout outcomes in African Americans with gout: A 12-month multicenter, randomized controlled trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
- Dalbeth N, Doyle A, Billington K, et al. A randomized double-blind controlled trial of intensive serum urate lowering with oral urate-lowering therapy for erosive gout [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).